Use of Limosilactobacillus reuteri DSM 17938 in paediatric gastrointestinal disorders: an updated review
Authors:
- 3 August 2022
- journal article
- review article
- Published by Walter de Gruyter GmbH in Beneficial Microbes
- Vol. 13 (3) , 221-242
Abstract
Strains of lactobacilli are the most widely used probiotics and can be found in a large variety of food products and food supplements throughout the world. In this study, the evidence on Limosilactobacillus reuteri DSM 17938 (LR DSM 17938) has been reviewed. This species secretes reuterin and other substances singularly or in microvesicles, inhibiting pathogen growth and interacting with the intestinal microbiota and mucosa, restoring homeostasis. The use of LR DSM 17938 has been exploited in several pathological conditions. Preclinical research has shown that this probiotic can ameliorate dysbiosis and, by interacting with intestinal mucosal cells, can raise the pain threshold and promote gastrointestinal motility. These aspects are amongst the significant components in functional gastrointestinal disorders, such as colic and regurgitation in infants, functional abdominal pain and functional constipation in children and adolescents. This strain can decrease the duration of acute diarrhoea and hospitalization for acute gastroenteritis but does not seem to prevent nosocomial diarrhoea and antibiotic-associated diarrhoea. Because of its ability to survive in the gastric environment, it has been tested in Helicobacter pylori infection, showing a significant decrease of antibiotic-associated side effects and a tendency to increase the eradication rate. Finally, all these studies have shown the excellent safety of LR DSM 17938 even at higher dosages. In conclusion data from various clinical trials here reviewed can guide the clinician to find the correct dose, frequency of administration, and therapy duration.Keywords
This publication has 151 references indexed in Scilit:
- Lactobacillus reuteri DSM 17938 Changes the Frequency of Foxp3+ Regulatory T Cells in the Intestine and Mesenteric Lymph Node in Experimental Necrotizing EnterocolitisPLOS ONE, 2013
- Safety and Tolerability of Lactobacillus reuteri DSM 17938 and Effects on Biomarkers in Healthy Adults: Results from a Randomized Masked TrialPLOS ONE, 2012
- Management of Helicobacter pylori infection—the Maastricht IV/ Florence Consensus ReportGut, 2012
- Lactobacillus reuteristrains reduce incidence and severity of experimental necrotizing enterocolitis via modulation of TLR4 and NF-κB signaling in the intestineAmerican Journal of Physiology-Gastrointestinal and Liver Physiology, 2012
- Probiotics stimulate enterocyte migration and microbial diversity in the neonatal mouse intestineThe FASEB Journal, 2012
- Gastrointestinal Microbiome Signatures of Pediatric Patients With Irritable Bowel SyndromeGastroenterology, 2011
- Human-derived probiotic Lactobacillus reuteri strains differentially reduce intestinal inflammationAmerican Journal of Physiology-Gastrointestinal and Liver Physiology, 2010
- Survival of Lactobacillus reuteri DSM 17938 and Lactobacillus rhamnosus GG in the Human Gastrointestinal Tract with Daily Consumption of a Low-Fat Probiotic SpreadApplied and Environmental Microbiology, 2009
- Genes and Molecules of Lactobacilli Supporting Probiotic ActionMicrobiology and Molecular Biology Reviews, 2008
- Removal of Antibiotic Resistance Gene-Carrying Plasmids from Lactobacillus reuteri ATCC 55730 and Characterization of the Resulting Daughter Strain, L . reuteri DSM 17938Applied and Environmental Microbiology, 2008